CD274 and non-small cell lung carcinoma: There are five phase 1/2 studies that also showed that anti-PD-1/PD-L1 therapy plus radiotherapy was tolerable for patients with advanced non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and small cell lung cancer (SCLC) (73–77).